Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial*
2020/10/01 by J.I. Silverberg, Jonathan I. Silverberg, D. Toth +19 · 30 citations
Medicine · Immunology and Microbiology · #Dermatology and Skin Diseases #Psoriasis: Treatment and Pathogenesis #Allergic Rhinitis and Sensitization
paper · pdf · doi:10.1111/bjd.19573
Abstract
BACKGROUND: Tralokinumab is a fully human monoclonal antibody that specifically neutralizes interleukin-13, a key driver of atopic dermatitis (AD). OBJECTIVES: To evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids (TCS) in patients with moderate-to-severe AD who were candidates for systemic therapy. METHODS: This was a double-blind, placebo plus TCS controlled phase III trial. Patients were randomized 2 : 1 to subcutaneous tralokinumab 300 mg or placebo every 2 weeks (Q2W) with TCS as needed over 16 weeks. Patients who achieved an Investigator's Global Assessment (IGA) score of 0/1 and/or 75% improvement in Eczema Area and Severity Index (EASI 75) at week 16 with tralokinumab were rerandomized 1 : 1 to tralokinumab Q2W or every 4 weeks (Q4W), with TCS as needed, for another 16 weeks. RESULTS: At week 16, more patients treated with tralokinumab than with placebo achieved IGA 0/1: 38·9% vs. 26·2% [difference (95% confidence interval): 12·4% (2·9-21·9); P = 0·015] and EASI 75: 56·0% vs. 35·7% [20·2% (9·8-30·6); P < 0·001]. Of the patients who were tralokinumab responders at week 16, 89·6% and 92·5% of those treated with tralokinumab Q2W and 77·6% and 90·8% treated with tralokinumab Q4W maintained an IGA 0/1 and EASI 75 response at week 32, respectively. Among patients who did not achieve IGA 0/1 and EASI 75 with tralokinumab Q2W at 16 weeks, 30·5% and 55·8% achieved these endpoints, respectively, at week 32. The overall incidence of adverse events was similar across treatment groups. CONCLUSIONS: Tralokinumab 300 mg in combination with TCS as needed was effective and well tolerated in patients with moderate-to-severe AD.
Citations
Cited by
- Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
- Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials
- Adriforant is a functional antagonist of histamine receptor 4 and attenuates itch and skin inflammation in mice
- European Guideline on Chronic Pruritus. In cooperation with the European Dermatology Forum (EDF)
- Biologic Therapies Targeting Type 2 Signaling in Atopic Dermatitis: A Comparative Review of Structural and Thermodynamic Differences in Mechanism of Action
- Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). [europepmc]
- Antibodies to watch in 2021. [europepmc]
- Selective IL-13 inhibitors for the treatment of atopic dermatitis. [europepmc]
- Itch in Atopic Dermatitis - What Is New? [europepmc]
- New Treatments for Atopic Dermatitis Targeting Skin Barrier Repair via the Regulation of FLG Expression. [europepmc]
- The Implications of Pruritogens in the Pathogenesis of Atopic Dermatitis. [europepmc]
- Tralokinumab: First Approval. [europepmc]
- Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis. [europepmc]
- Safety and Danger Considerations of Novel Treatments for Atopic Dermatitis in Context of Primary Cutaneous Lymphomas. [europepmc]
- Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis. [europepmc]
- Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis. [europepmc]
- The efficacy and safety of IL-13 inhibitors in atopic dermatitis: A systematic review and meta-analysis. [europepmc]
- Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. [europepmc]
- The IL-4/-13 Axis and Its Blocking in the Treatment of Atopic Dermatitis. [europepmc]
- Atopic Dermatitis: Clinical Aspects and Unmet Needs. [europepmc]
- The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment. [europepmc]
- Biologic Versus Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Clinical Considerations. [europepmc]
- Real-Life Experience of Tralokinumab for the Treatment of Adult Patients with Severe Atopic Dermatitis: A Multicentric Prospective Study. [europepmc]
- Overview of Atopic Dermatitis in Different Ethnic Groups. [europepmc]
- Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial. [europepmc]
- The hidden sentinel of the skin: An overview on the role of interleukin-13 in atopic dermatitis. [europepmc]
- Neuroimmune interplay during type 2 inflammation: Symptoms, mechanisms, and therapeutic targets in atopic diseases. [europepmc]
- "Input/output cytokines" in epidermal keratinocytes and the involvement in inflammatory skin diseases. [europepmc]
- Systemic Immunomodulatory Treatments for Atopic Dermatitis: Living Systematic Review and Network Meta-Analysis Update. [europepmc]
- European Guideline (EuroGuiDerm) on atopic eczema: Living update. [europepmc]
Related